UDCA
Sponsors
Dr. Falk Pharma GmbH, Kanazawa University, Xijing Hospital of Digestive Diseases, Beijing 302 Hospital, Fuzhou General Hospital
Conditions
Chronic Liver DiseaseDiabetes MellitusHealthyPBCPrimary Biliary CholangitisPrimary Biliary CirrhosisPrimary Sclerosing CholangitisType 2 Diabetes Mellitus
Phase 1
Pharmacokinetic Investigation of UDCA in Bile and Serum
CompletedNCT00529009
Start: 2007-05-31Updated: 2019-05-07
Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
WithdrawnNCT02965911
Start: 2016-01-31End: 2021-09-08Updated: 2021-09-17
Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis
NCT03516006
Start: 2017-01-31End: 2024-01-31Target: 20Updated: 2018-05-04
Phase 2
Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin
NCT05500937
Start: 2021-03-01End: 2024-12-31Target: 1000Updated: 2022-09-28
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
RecruitingNCT05749822
Start: 2023-02-17End: 2027-12-31Target: 104Updated: 2026-01-08
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Active, not recruitingNCT06174402
Start: 2023-08-21End: 2026-12-31Target: 184Updated: 2026-01-08
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
RecruitingNCT06365424
Start: 2017-04-08End: 2027-04-30Target: 117Updated: 2025-07-02
Phase 3
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
CompletedNCT02823353
Start: 2016-04-08End: 2022-06-30Updated: 2023-03-08
Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
NCT02823366
Start: 2016-01-31End: 2023-12-31Target: 104Updated: 2022-09-30
Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis
NCT02916290
Start: 2016-01-31Target: 200Updated: 2016-09-27
Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid
NCT02916641
Start: 2016-01-31Target: 200Updated: 2016-09-27
Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
NCT04956328
Start: 2021-07-22End: 2023-09-20Target: 120Updated: 2021-07-26
Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis
CompletedNCT05450887
Start: 2021-09-23End: 2024-04-09Updated: 2024-07-11
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
CompletedNCT06715319
Start: 2021-10-09End: 2024-04-29Updated: 2024-12-04